EP1 receptor ligands

A compound of general formula I:

• wherein:
• W1 is a phenyl ring;
• W2 is a 6-membered heterocyclic ring that contains at least 1 N atom and can additionally contain 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
• wherein said 6-membered heterocyclic ring is aromatic, partially unsaturated or saturated, and which is optionally substituted by one or more R3;
• R1 is -R6-R7;
• each R2 is independently selected from the group consisting of H, halogen, C1-6-alkyl, C1-6-haloalkyl, —O—C1-6-alkyl, —O—C1-6-haloalkyl, hydroxyC1-6-alkyl, CN, —NR14COR15, —NR14SO2R15 and —SO2R15;
• each R3 is independently selected from the group consisting of H, halogen, C1-6-alkyl C1-6-haloalkyl, —O—C1-6-alkyl, —O—C1-6-haloalkyl, hydroxyC1-6-alkyl, —C1-4-alkylene-OR14, —C2-4-alkenylene-COOH, ═O and CN;
• each R4 is independently selected from the group consisting of H and C1-6-alkyl, or both R4 together with the C atom to which they are bonded form a C3-6cycloalkyl;
• R5 is selected from the group consisting of H, halogen, C1-6-haloalkyl, —O—C1-6-alkyl, —O—C1-6-haloalkyl, -OH, C1-6-alkyl, C3-6cycloalkyl and —SO2R15;
• R6 is selected from the group consisting of a direct bond, —C1-4-alkylene-, —O—C1-4-alkylene-and —C2-4-alkenylene-;
• R7 is selected from the group consisting of —CO2H, —SO3H, 5-tetrazolyl, —OPO3H2, —PO3H2, —CONR12R12, —CONH—SO2R12, —NR14CONR14—SO2R15 and —SO2—NHCOR15
• Y is selected from the group consisting of —C2-4-alkylene-, —O—C1-4-alkylene-, —C2-4-alkenylene-, —C1-4-alkylene-O—, —NR13—C1-4-alkylene- and —C1-4-alkylene-NR13—;
• B is selected from the group consisting of C2-6-alkyl, C2-6 alkenyl and Cy, any of them optionally substituted by one or more R8;
• each R8 is independently selected from the group consisting of halogen, C1-6-haloalkyl, —O—C1-6-alkyl, —O—C1-6-haloalkyl, C1-6-alkyl, —OH, —CN, —CH2OR14 and —CONR12R12;
• each R9 is independently selected from the group consisting of CR10 and N;
• each R10 is independently selected from the group consisting of H, halogen, C1-6-alkyl, C1-6-haloalkyl, —O—C1-6-alkyl, —O—C1-6-haloalkyl and hydroxyC1-6-alkyl;
• R11 is CR5 or N,
• each R12 is independently selected from the group consisting of H, C1-6-alkyl, C1-6-haloalkyl, —NR14R14 and C3-6cycloalkyl;
• each R13 is independently selected from the group consisting of H, C1-6-alkyl, C1-6-haloalkyl, and C3-6cycloalkyl;
• each R14 is independently selected from the group consisting of H and C1-6-alkyl;
• each R15 is independently selected from the group consisting of C1-6-alkyl;
• Cy is a 3-6 membered monocyclic or 8-12 membered polycyclic ring which can be carbocyclic or heterocyclic containing 1 to 3 heteroatoms selected from N, O and S and which can be aromatic, partially unsaturated or saturated and wherein one or more C or S atoms in Cy can be oxidized to form CO, SO or SO2;
• with the proviso that when W1 and W2 is a benzimidazole, R6 and R7 are not at the same time respectively a —O—C1-4-alkylene- and a —CO2H or that R7 is not —CONH—SO2R12;
• and the salts and prodrugs thereof.